Will Palatin Tech's pipeline drug for female Hypoactive Sexual Desire Disorder - bremelanotide - be approved by the FDA by May 2019?
Palatin Tech submitted a New Drug Application (NDA) application for bremelanotide for the treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women in March 2018. Will this NDA application be approved for prescribing to patients - whether in a full or limited form by the end of May 2019? The FDA will complete it's review March 23, 2019
Open interest (ETH)
Open interest (USD)
This market is not yet available to trade on Veil.